Evidence map›Paper›PMID 30858851›Full record

ReviewFrontiers in immunology2019

Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells.

Francesca Garretti, Dritan Agalliu, Cecilia S Lindestam Arlehamn, Alessandro Sette, David Sulzer

2 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 101 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 1 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04239079 recruitingnot on this map

Autoimmune Features of Neurodegenerative Disorders

TypeobservationalSponsorColumbia UniversityRan2019 to 2028Enrolled120ConditionsParkinson Disease, Alzheimer Disease, Mild Cognitive Impairment
NCT04995081 phase2completednot on this mapstarted 2021, after this paper: background citation

A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease

TypeinterventionalSponsorHope Biosciences Research FoundationRan2021 to 2025Enrolled60ConditionsParkinson DiseaseArmsBiological/Vaccine: Allogeneic HB-adMSCs, Placebo
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 1 synthesis or guideline pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Francesca GarrettiDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, United States.
Dritan AgalliuDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, United States.
Cecilia S Lindestam ArlehamnDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, United States.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, United States.
David SulzerDepartment of Neurology, Columbia University Irving Medical Center, New York, NY, United States.
Columbia University Irving Medical Center · USLa Jolla Institute for Immunology · USUniversity of California, San Diego · US

Funding

The Dopamine Synapse and Associative LearningR01DA007418 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David Sulzer · 1999 to 2026
$9.4M
Autoimmune Features of Neurodegenerative DisordersR01NS095435 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SETTE, ALESSANDRO, SULZER, DAVID · 2018 to 2022
$4.2M
Cellular and humoral immune mechanisms underlying neurovascular dysfunction in autoimmune encephalitisR01MH112849 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AGALLIU, DRITAN, CUTFORTH, TYLER · 2017 to 2020
$2.1M
CNS angiogenesis and blood-brain barrier regulation by the Wnt inhibitor Apcdd1.R01HL116995 · NHLBI · UNIVERSITY OF CALIFORNIA-IRVINE · PI AGALLIU, DRITAN · 2013 to 2017
$1.9M
miR regulation of the neurovasculature function in health and diseaseR01NS107344 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI PEDERSEN, IRENE MUNK · 2018 to 2021
$1.7M
Developing a microfluidic human neurovascular unit system to investigate genetic and age-related risk factors in Alzheimer's diseaseR01AG078352 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Dritan Agalliu, Andrew Alexander Sproul · 2025 to 2026
$837k
NHLBI NIH HHS R01 HL116995NIA NIH HHS R01 AG078352NIDA NIH HHS R01 DA007418NIMH NIH HHS R01 MH112849NINDS NIH HHS R01 NS095435NINDS NIH HHS R01 NS107344
6 · The paper itself

Abstract

Evidence from a variety of studies implicates a role for the adaptive immune system in Parkinson's disease (PD). Similar to multiple sclerosis (MS) patients who display a high number of T cells in the brain attacking oligodendrocytes, PD patients show higher numbers of T cells in the ventral midbrain than healthy, age-matched controls. Mouse models of the disease also show the presence of T cells in the brain. The role of these infiltrating T cells in the propagation of disease is controversial; however, recent studies indicate that they may be autoreactive in nature, recognizing disease-altered self-proteins as foreign antigens. T cells of PD patients can generate an autoimmune response to α-synuclein, a protein that is aggregated in PD. α-Synuclein and other proteins are post-translationally modified in an environment in which protein processing is altered, possibly leading to the generation of neo-epitopes, or self-peptides that have not been identified by the host immune system as non-foreign. Infiltrating T cells may also be responding to such modified proteins. Genome-wide association studies (GWAS) have shown associations of PD with haplotypes of major histocompatibility complex (MHC) class II genes, and a polymorphism in a non-coding region that may increase MHC class II in PD patients. We speculate that the inflammation observed in PD may play both pathogenic and protective roles. Future studies on the adaptive immune system in neurodegenerative disorders may elucidate steps in disease pathogenesis and assist with the development of both biomarkers and treatments.

Indexed as

Autoimmunityalpha-SynucleinAnimalsBrainHumansInflammationParkinson DiseaseT-Lymphocytesalpha-Synucleinadaptive immune systemautoimmunityblood-brain barrierneuroinflammationParkinson's diseaseT cellsα-synuclein

Identifiers

PMID30858851
PMCPMC6397885
OpenAlexW2916020602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.